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Abstract
Synovial sarcoma is a relatively rare high-grade soft tissue sarcoma that often develops in the limbs of young people
and induces the lung and the lymph node metastasis resulting in poor prognosis. In patients with synovial sarcoma,
specific chromosomal translocation of t(X; 18) (p11.2;q11.2) is observed, and SS18-SSX fusion protein expressed by
this translocation is reported to be associated with pathogenesis. However, role of the fusion protein in the
pathogenesis of synovial sarcoma has not yet been completely clarified. In this study, we focused on the localization
patterns of SS18-SSX fusion protein. We constructed expression plasmids coding for the full length SS18-SSX, the
truncated SS18 moiety (tSS18) and the truncated SSX moiety (tSSX) of SS18-SSX, tagged with fluorescent proteins.
These plasmids were transfected in synovial sarcoma SYO-1 cells and we observed the expression of these proteins
using a fluorescence microscope. The SS18-SSX fusion protein showed a characteristic speckle pattern in the
nucleus. However, when SS18-SSX was co-expressed with tSSX, localization of SS18-SSX changed from speckle
patterns to the diffused pattern similar to the localization pattern of tSSX and SSX. Furthermore, cell proliferation and
colony formation of synovial sarcoma SYO-1 and YaFuSS cells were suppressed by exogenous tSSX expression.
Our results suggest that the characteristic speckle localization pattern of SS18-SSX is strongly involved in the
tumorigenesis through the SSX moiety of the SS18-SSX fusion protein. These findings could be applied to further
understand the pathogenic mechanisms, and towards the development of molecular targeting approach for synovial
sarcoma.
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Introduction
Synovial sarcoma is a relatively rare high-grade soft tissue
sarcoma that often develops in the limbs of young people.
Recent advancements in surgery, chemotherapy, radiotherapy,
and multidisciplinary therapy have improved the prognosis. The
overall 5-year survival rate in synovial sarcoma patients without
metastasis is reported to be 61–80% [1-4]. However, in long-
term, synovial sarcoma cells sometimes metastasize to the
lung and the lymph node, turning into a life-threatening
condition resulting in a poor prognosis. The pathogenic
mechanisms have not yet been completely elucidated.
However, specific chromosomal translocation of t(X; 18)
(p11.2;q11.2) has been identified in patients with synovial
sarcoma [5]. The fusion of the SS18 gene on chromosome 18
to the SSX gene on chromosome X results in the expression of
fusion protein SS18-SSX composed of the NH3-terminal half of
the amino acids from SS18 and COOH-terminal amino acids of
the SSX. Expression of the fusion protein has been observed in
more than 97% of synovial sarcoma cells [6-8]. This suggests
that the SS18-SSX fusion protein is specifically expressed in
the synovial sarcoma cells, and is important in the
pathogenesis of the disease. SS18 and SSX proteins are
localized in the nucleus and are associated with transcriptional
regulation, although neither have a distinct DNA binding-
domain [6-8]. Therefore, they are thought to regulate
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transcription by interacting with other proteins that can bind
directly to the DNA in the nucleus.
The wild-type SS18 protein comprises 387 amino acid
residues, being ubiquitously expressed in normal cells [6]. It
has been reported that SS18 interacts with SNF/SWI
complexes (a chromatin remodeling factor) [9-13], Sin3A (a
factor of histone deacetylase complex) [14,15], p300 [16], and
AF10 [17]. SS18 is regarded as a transcriptional co-activator
because it promotes transcription.
Wild-type SSX protein consists of 188 amino acid residues
[7], and it is expressed in the testis and the thyroid, along with
melanoma and lung cancer tumor cells, and is one of the
cancer/testis antigens [18-21]. Major fusion partners of SS18 in
synovial sarcoma are SSX1 and SSX2, and SSX4 has been
reported in rare cases [22,23]. The SSX1 to SSX9 genes have
been identified [24]. SSX is reported to interact with
transcriptional repressors such as the polycomb-group (PcG)
[25-29], core histone [11], RAB3IP, and SSX2IP [27,28,30],
and is regarded as a transcriptional co-repressor since it
suppresses transcription.
SS18-SSX fusion protein is also known to be localized in the
nucleus [25,26,31,32], and is reported to interact with a variety
of proteins [10-12,25,26,29,33]. Recently, gene expression
profiles using DNA microarray has revealed various
downstream genes that are targeted by the SS18-SSX fusion
protein [34-42]. The control of gene expression by SS18-SSX
is believed to involve chromatin remodelingbecause of SS18-
SSX’s colocalization with both Trithorax (TrxG) and Polycomb
group (PcG) complexes, thereby maintaining chromatin in a
poised bivalent state [26,39,43]. Lubieniecka et al. reported
that EGR1 is repressed by the SS18-SSX protein through
trimethylation of histone H3, and HDAC inhibitor reverses the
histone modifications and reactivates EGR1 expression in
synovial sarcoma cells [43]. Su et al. identified ATF2 as the
DNA-binding partner of SS18-SSX and showed that HDAC
inhibitors reverse the epigenetic repressor activity of the SS18-
SSX oncoprotein complex by preventing TLE1
recruitment[44]. . Several studies have showed that synovial
sarcoma cells express mRNA transcripts of pluripotency factors
such as Sox2, Oct3/4, and Nanog [45] and show stem-cell-like
gene expression profiles [46], and that tumor cells lacking the
BAF47 tumor suppressor subunit express stem-cell-like
signatures [47]. Kadoch and Crabtree [48] demonstrated that
SS18-SSX fusion protein binds to SWI/SNF-like BAF
(chromatin-remodeling) complexes and evicts both the wild-
type SS18 and the tumor suppressor BAF47. This altered
complex binds to and activates the Sox2 locus by disrupting
H3K27me3-mediated repression, and drives proliferation of
these cells [48]. In transgenic mice, conditional overexpression
of SS18-SSX2 in the myogenic progenitor compartment, but
not that in other compartments, leads to the appearance of
both monophasic and biphasic synovial sarcoma tumors with
full penetrance [49].
Generally, proteins that function as transcriptional factors are
believed to form complicated complexes, localize at specific
region, and carry out their own functions. Synovial sarcoma cell
line SYO-1 bearing the SS18-SSX2 translocation was
established previously [50]. We investigated the localization
pattern of each component of synovial sarcoma-related fusion
protein, and examined the inhibiting effect of the localization of
SS18-SSX protein in order to understand the mechanisms by
which SS18-SSX contributes towards the synovial sarcoma
pathogenesis.
Results
Localization patterns of synovial sarcoma-related
proteins in the SYO-1 cells
Localization of full-length SS18 and SSX proteins tagged to
GFP was observed under fluorescence microscope, after the
constructs pEGFP-SS18, pEGFP-SSX1, and pEGFP-SSX2
were transfected into SYO-1 cells. SS18 localized to the
nucleus and showed a speckled distribution pattern (Figure
1A). Both SSX1 and SSX2 localized in the nucleus and
displayed a diffuse localization pattern. SSX1 also displayed a
speckled pattern and the number of these speckles were
relatively more in cells transfected with SSX1 than (Figure 1B)
compared to cells with SSX2 (Figure 1C). Next, SS18-SSX
fusion proteins were observed after transfection of pEGFP-
SS18-SSX1 and pEGFP-SS18-SSX2 into SYO-1 cells. Both
SS18-SSX1 and SS18-SSX2 were localized in the nucleus
showing clear speckles similar to that observed for SS18.
However, when we examined closely, compared to SS18, the
fusion proteins displayed a pattern in which densely packed
oval dots were more evenly distributed (Figure 1G and 1H).
There was no remarkable difference in the localization between
SS18-SSX1 and SS18-SSX2. To examine the effect of the
fluorescent protein on the gene localization, HEK293 cells
transfected with SS18, SSX2, and SS18-SSX2 without GFP
were analyzed by fluorescence immunocytochemistry with anti-
SS18 and anti-SSX antibodies. SS18 and SS18-SSX2 staining
showed a speckled pattern and SSX2 displayed a diffuse
pattern, which is similar to the localization of the GFP-tagged
proteins (Figure S1), suggesting that addition of the fusion
protein does not affect gene localization. Then, the GFP-fusion
plasmids harboring SS18 moiety and SSX moiety were
constructed. Localization of tSS18 (truncated SS18 composing
of 1-379 amino acids), tSSX1, and tSSX2 (truncated SSX
composing of 111-188 amino acids) was observed after
transfection of pEGFP-tSS18, pEGFP-tSSX1 and pEGFP-
tSSX2 into SYO-1 cells. The tSS18 showed a similar
localization pattern in the nucleus as that of SS18, although the
intensity of the fluorescence was weak (Figure 1D).
Localization pattern of tSSX1 and tSSX2 did not differ
remarkably from those of SSX1 and SSX2, respectively (Figure
1E and F). We also looked at the localization patterns of these
synovial sarcoma-related proteins in HEK293 cells transfected
with these plasmids, the localization patterns were similar to
that observed in SYO-1 cells (Figure S2). We confirmed that
the proteins from these plasmid constructs were successfully
expressed in HEK293 cells by western blotting with anti-SS18
and anti-SSX antibodies (Figure S3).
Suppression of Synovial Sarcoma by Truncated SSX
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Change in the localization pattern of SS18-SSX upon
co-expression with truncated SS18 and SSX proteins
Effect of tSS18 and tSSX truncated proteins on localization
of SS18-SSX was examined in synovial sarcoma cells. When
GFP-tagged SS18-SSX2 was co-transfected along with
DsRedmonomer-tSS18 into SYO-1 cells, the localization
pattern of SS18-SSX2 was not remarkably different from that
observed in cells that were transfected with SS18-SSX2 alone,
but the localization of tSS18 was similar with that of SS18-
SSX2 (Figure 2, A1, and A2). We then looked at the changes in
the localization pattern if any of the GFP-tagged SS18-SSX2
when co-expressed with DsRedmonomer-tSSX2 fusion in
SYO-1 cells. The localization of SS18-SSX2 significantly
changed from a speckled pattern to a diffuse localization
pattern, and was similar to that of tSSX2 (Figure 2, B1, and
B2). When GFP-tagged SS18-SSX2 and DsRedmonomer-
tSSX1 fusion were co-expressed, localization of SS18-SSX2
also changed from speckled to a diffuse pattern, and was
similar to that of tSSX1 (data not shown). When SS18-SSX1
was co-expressed with tSSX1, the localization of SS18-SSX1
also showed to a diffuse pattern (Figure S4). However, when
pEGFP-SS18-SSX2 and pDsRedmonomer empty vector were
co-expressed, localization of SS18-SSX2 did not change
(Figure 2, C1 and C2). When we transfected SYO-1 cells with
DsRedmonomer-fused SS18, SSX1 and SSX2 full-length
genes instead of using the truncated genes, the localization of
SS18-SSX was similar to the localization pattern observed
earlier (data not shown). We obtained similar results for the
localization of these fusion proteins in HEK293 cells
transfected with the above plasmids (Figures S5 and S6). All
the cells displaying a diffuse pattern we examined were
Figure 1.  Localization of synovial sarcoma-related
proteins in synovial sarcoma SYO-1 cells.  GFP fused
proteins were observed using a fluorescence microscope. A,
GFP-SS18; B, GFP-SSX1; C, GFP-SSX2; D, GFP-tSS18; E,
GFP-tSSX1; F, GFP-tSSX2; G, GFP-SS18-SSX1; H, GFP-
SS18-SSX2; I, GFP. Scale bars indicate 5 µm.
doi: 10.1371/journal.pone.0077564.g001 observed to have red-fluorescence of tSSX2 in their nuclei.
Therefore, we analyzed quantitatively the effect of increasing
expression of tSSX on localization of SS18-SSX. Transfection
of increasing amount of DsRedmonomer-tSSX2 plasmid (0, 2,
4, and 6 µg) showed significant loss of cells with speckled
pattern. However, when cells were transfected with increasing
amounts of DsRedmonomer-tSS18 plasmid, there was no
change in the localization pattern (Figure 3). We examined the
effect of DsRedmonomer-tSSX2 and -tSS18 on GFP-SS18-
SSX2 expression in transfected HEK293 cells by western
blotting analysis. As can be seen in the Figure S7, expression
of SS18-SSX2 was not affected by tSSX2 and tSS18.
Suppression of cell proliferation of SYO-1 cells by
exogenous expression of tSSX2
As described above, the localization of SS18-SSX2 was
affected by the co-expression of tSSX2 in SYO-1 cells.
Therefore, we examined the effect of expression of tSSX2 on
proliferation of SYO-1 cells harboring the SS18-SSX2 fusion
gene. SYO-1 cells were transfected with GFP-fused tSSX2 or
GFP vector alone as control, split 48 h after transfection, and
the cells expressing the fluorescence proteins were observed
and counted on day 4, 6, and 8 after transfection. The cell
proliferation ratio was normalized by dividing the numbers of
GFP expressing cells on days 6 and 8 by the number on day 4
in SYO-1 cells transfected with tSSX2 and control group. The
cell proliferation was significantly suppressed in the tSSX2
group on days 6 and 8 (Figure 4). A time-course experiment
showing the change in the number of GFP expressing cells is
shown in Figure 5.
Figure 2.  Representative images showing the co-
expression of GFP-tagged SS18-SSX2 and of DsRed-
monomer-tagged truncated proteins in transfected SYO-1
cells.  Fluorescent proteins were observed using a
fluorescence microscope. A, co-expression of GFP-SS18-
SSX2 (A1) and DsRed-monomer-tSS18 (A2); B, co-expression
of GFP-SS18-SSX2 (B1) and DsRed-monomer-tSSX2 (B2); C,
co-expression of GFP-SS18-SSX2 (C1) and DsRed-monomer
empty vector (C2); D, co-transfection of GFP-SS18-SSX2 (D1)
and DsRed-monomer-tSSX2 (D2) SYO-1 cell in which tSSX2
was not expressed after co-transfection. Scale bars indicate 5
µm.
doi: 10.1371/journal.pone.0077564.g002
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Suppression of colony formation of synovial sarcoma
cells by exogenous expression of tSSX
We examined the effect of tSSX2 expression on colony
formation of SYO-1 cell line. SYO-1 cells were transfected with
GFP-tagged tSSX2 or GFP vector alone, split 48 h after
transfection, and selected with G418 for three weeks. The
colonies were observed after cell fixation and staining. The
Figure 3.  Effect of increasing expression of tSSX on the
localization of SS18-SSX.  Plasmid pEGFP-SS18-SSX2 (2
µg) was co-transfected in HEK293 cells with pDsRedmonomer-
tSSX2 (0, 2, 4, and 6 µg) (A), or DsRedmonomer-tSS18 (0, 2,
4, and 6 µg) (B). The total DNA amount of transfection was
complimented by pCMV-Tag2B empty plasmid without
fluorescent protein (6, 4, 2, and 0 µg). The cells showing either
a speckled pattern or a diffuse pattern of SS18-SSX2
localization were counted in 30 fields of fluorescence
microscope, and the relative ratio of cells with speckled pattern
was calculated (C). Scale bars indicate 10 µm.
doi: 10.1371/journal.pone.0077564.g003
number of colonies formed as well as the size of the colony
was decreased in the tSSX2 group as compared with that of
the control group (Figure 6A). We also studied the colony
forming ability of another synovial sarcoma cell line YaFuSS
harboring the SS18-SSX1 fusion gene. Reduced number of
colonies was observed in YaFuSS cell line transfected with
GFP-tagged tSSX1 (Figure 6B).
Discussion
In the present study, the wild-type SS18 clearly showed a
speckled localization pattern, while SSX showed primarily a
diffuse pattern. The localization pattern of SS18-SSX fusion
proteins was clearly nuclear with a speckled pattern and clear
elliptical dots were densely distributed, which differed from
those of the wild-type SS18 and SSX. In addition, localization
of tSS18 and tSSX, which are components of SS18-SSX fusion
protein did not remarkably differ from that of the wild-type SS18
and SSX, respectively. Hence, the localization pattern of SS18-
SSX is thought to be the distinct feature obtained only when
both SS18 and SSX form a fusion protein. The subtle
difference of tSSX1 and tSSX2 localization is considered to
depend on 11 different amino acids between them.
Several investigators have reported regarding the
localization of synovial sarcoma-associated proteins. dos
Santos et al. have reported that the SS18 displays a nuclear
punctated localization pattern and SSX a diffuse pattern in the
nucleus of transfected COS-1 cells [31]. They suggested that
SS18 might influence the manifestation of the tumor since the
Figure 4.  Exogenous expression of tSSX2 suppresses the
proliferation of synovial sarcoma SYO-1 cells.  SYO-1 cells
were transfected with pEGFP-tSSX2 or pEGFP vector, split 48
h after transfection, and the cells expressing the GFP-tagged
fusion proteins were counted on day 4, 6 and 8 after
transfection. The cell proliferation ratio was normalized by
dividing the number of cells expressing GFP-tagged proteins
on days 6 and 8 by the number on day 4. Error bars indicate
standard deviation, *p < 0.001, **p < 0.0001.
doi: 10.1371/journal.pone.0077564.g004
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SS18-SSX fusion protein is also localized in the nucleus and
displays a similar punctated pattern [31]. Brett et al. also
reported that SS18 and SSX1 displayed a speckled and
uniform distribution pattern in the nucleus, respectively, and
that the localization pattern of SS18-SSX2 fusion protein is
similar to that of SS18 in transfected NIH3T3, Cos-7, HT1080,
and MRC-5 cells [32]. On the other hand, Soulez et al. reported
that the co-localization of SS18-SSX fusion protein and SSX
with RING1 and BMI1, which belong to polycomb group (PcG),
but not SS18 [26]. dos Santos et al. subsequently reported that
HeLa and COS-1 cells harboring the SSX expression vector
displayed speckles in the diffuse distribution, and the
localization of speckles of SS18-SSX coincided with that of
SSX [25]. Furthermore, when the C-terminus of the SSX region
called the SSX repression domain was removed, the
localization of SS18-SSX coincided with that of SS18 [26,51].
Therefore, they concluded that SSX region played a dominant
role over SS18 region in localization of SS18-SSX and that the
C-terminus of SSX was especially important [25].
In our study, we demonstrate that the localization pattern of
SS18-SSX changes significantly when co-expressed with
tSSX, suggesting that the localization of SS18-SSX can be
antagonized at least by tSSX. These results indicate that
SS18-SSX might bind to other proteins via its SSX region; this
agrees well with the results of Soulez et al. and dos Santos et
al. [25,26]. As the localization of SS18-SSX changed to a
Figure 5.  Representative images showing changes in
proliferation of SYO-1 cells expressing GFP-tSSX2
monitored for a period of 18 days.  SYO-1 cells were
transfected with pEGFP-tSSX2 (A) or pEGFP vector (B), split
48 h after transfection, and the cells expressing GFP-tagged
proteins were observed under fluorescence microscope on day
4, 6, 8, 10, and 18 after transfection. 1, day 4; 2, day 6; 3, day
8; 4, day 10; 5, day18. Scale bars indicate 20 µm.
doi: 10.1371/journal.pone.0077564.g005
diffuse pattern upon co-expression of tSSX and this seems to
coincide with the localization pattern of SSX and tSSX, the
localization of SS18-SSX might be guided through the SSX
region of SS18-SSX. Interestingly, since co-expression of
tSSX2 suppressed cell proliferation and colony formation of the
synovial sarcoma SYO-1 and YaFuSS cell lines, the speckle
distribution pattern characterized by SS18-SSX might be
strongly involved in tumorigenesis of synovial sarcoma cells.
Recently, Kadoch and Crabtree [48] demonstrated that SS18-
SSX protein binds to SWI/SNF-like BAF (chromatin-
remodeling) complexes, and that SS18-SSX-driven altered
BAF complex formation depends on 2 amino acids of SSX [48].
Our results showing disappearance of SS18-SSX speckles by
exogenous tSSX transfection agrees with their results, and the
phenomenon we found might show the disruption of SS18-
SSX-driven altered BAF complex antagonized by tSSX. The
effect of tSSX on SS18-SSX speckle disruption might depend
on 2 amino acids of SSX at positions 43 and 44. The authors
also demonstrated that assembly of wild-type complexes and
proliferative quiescence can be achieved by increasing the
concentration of wild-type SS18. However, we have not
performed a cell growth assay using tSS18 transfection
because we could not find any change of SS18-SSX
localization by tSS18 transfection due to similarity of
localization of SS18-SSX and tSS18. Our finding that tSS18
and SS18 colocalize with SS18-SSX spatially in the nucleus
might explain the results that increased expression of SS18
displaces SS18-SSX from SWI/SNF-like BAF complexes and
lead to reduced growth. Perani et al. reported that SS18 forms
Figure 6.  A. Exogenous expression of tSSX suppresses
the colony formation in SYO-1 cells.  SYO-1 cells cultured in
90 mm dishes were transfected with pEGFP empty vector (A1)
or pEGFP-tSSX2 (A2), split into 10 plates of 60 mm dishes 48
h after transfection and selected with G418 for three weeks.
The cells were fixed in 4% formaldehyde and stained with
Giemsastain solution. B, YaFuSS cells were transfected with
pEGFP empty vector (B1) or pEGFP-tSSX2 (B2), and
assessed for colony formation activity. The colonies were
counted and the average number of colonies formed is shown
as bar graphs for SYO-1 (A3) and YaFuSS (B3). Error bars
indicate standard deviation, * p < 0.01.
doi: 10.1371/journal.pone.0077564.g006
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an oligomer with SS18 itself or with SS18-SSX [9]. If SS18-
SSX forms an oligomer with tSS18, it could account for the
same localization pattern observed for SS18-SSX and tSS18.
SSX1 and SSX2 interact with BMI1 and RING1A, which
belong to PcG and with LHX4, RAB3IP, and SSX2IP which are
transcription factors [27,28]. RAB3IP and SSX2IP interact with
the N-terminal domain of SSX [27,30]. Since SS18-SSX fusion
proteins do not consist of the interaction domains, RAB3IP and
SSX2IP are quite unlikely to be the candidate proteins
interacting with SS18-SSX. Our results using SSX were similar
between the two subtypes of SSX, and it is known that PcGs
such as BMI1 and RING1A interact with SSX1 and SSX2
commonly. Therefore, BMI1 and RING1A could be the
candidate proteins interacting with the SSX1 or SSX2 region of
SS18-SSX fusion protein.
Our results revealed the possibility that SS18-SSX is
involved in tumor proliferation because of its interaction with
some specific proteins interacting with the wild-type SSX via
the SSX region of SS18-SSX. Further study is needed to
identify these interacting proteins, which will provide a better
understanding on the pathways involved in the pathogenesis of
synovial sarcoma. This could provide new target molecules that
could help in the development of newer treatment options for
synovial sarcoma using molecular targeting approach.
Materials and Methods
Cell lines
Human synovial sarcoma cell line SYO-1 expressing the
SS18-SSX2 fusion gene was established in our laboratory [50].
Human synovial sarcoma cell line YaFuSS expressing the
SS18-SSX1 fusion gene was kindly provided by Dr. J.
Toguchida (Institute for Frontier Medical Sciences, Kyoto
University, Japan) [52]. Human normal embryonic kidney cell
line HEK293 was purchased from American Type Culture
Collection. These cell lines were grown in Dulbecco’s modified
Eagle’s medium or RPMI-1640 (Invitrogen, Carlsbad, CA, USA)
supplemented with 10% fetal bovine serum (Invitrogen), 100
units/ml of penicillin G and 100 µg/ml of streptomycin (Meiji
Seika, Tokyo, Japan). All cells were incubated at 37°C in a
humidified atmosphere containing 5% CO2.
Plasmid construction
The coding regions of the human SS18-SSX1, SS18-SSX2,
SS18, SSX1, SSX2, tSS18 (truncated SS18 coding #1-379
amino acids), tSSX1 and tSSX2 (truncated SSX coding
#111-188 amino acids) were amplified by PCR with cDNA
derived from synovial sarcoma cells as described earlier [14].
The amplified cDNAs were inserted downstream of green
fluorescent protein (GFP) of pEGFP-C vector (Clontech), and
the expression plasmids were constructed to produce GFP
tagged-SS18-SSX1, -SS18-SSX2, -SS18, -SSX1, -SSX2, -
tSS18, -tSSX1 and -tSSX2 proteins. Furthermore,
pDsRedmonomer plasmids bearing the SS18, SSX1, SSX2,
tSS18, tSSX1 and tSSX2 cDNAs were inserted downstream of
DsRedmonomer, to produce DsRedmonomer fusion proteins.
To detect the localization of SS18, SSX2, and SS18-SSX2 by
fluorescence immunocytochemistry, pCMV-Tag2B expression
plasmids with FLAG tag containing the cDNAs were used for
transfection as described [53]
Transfection
To increase the transfection efficiency, reverse transfection
method was used. The vectors (total DNA amount of 0.25 µg in
cases where one kind of vector was used, and 0.125 µg each
in case of two kinds of vectors) were mixed with 1 µL of
Effectene (QIAGEN), 3.25 µL EC-buffer, 1 µL enhancer and
0.6 µL of 1.5 M sucrose; 9 µL of gelatin was added 15 min
later, and the mixture was dropped into a well (12 mm × 10
mm) of a 8 well tissue culture chamber slide (Lab-Tec, Nunc)
and allowed to dry. The cells were plated in the wells, and the
localization of fluorescent proteins was observed under
fluorescence microscope after replacement of the medium with
DMEM without phenol red.
Fluorescence immunocytochemistry
To determine the localization of SS18 and SSX in
transfected HEK293 cells, the cells were seeded on glass
culture slides (BD Falcon 8-well CultureSlide; BD Biosciences),
and grown to 80% confluence. They were then fixed in 1%
formaldehyde for 10 min at room temperature, permeabilized,
blocked with 1% bovine serum albumin (BSA) in PBS for 30
min at room temperature, and then incubated with anti-SS18
antibody (SYT; C-19, Santa Cruz Biotechnology, California,
USA) or anti-SSX1 antibody (FL-188, Santa Cruz
Biotechnology) overnight. The cells were washed and then
incubated simultaneously with Alexa 594-conjugated
secondary antibody (Invitrogen, Eugene, OR) for 1 h and
Hoechst 33342 (1 mg/mL) (ICN Biomedicals, Aurora, OH) for
nuclear staining. Images were acquired with SenSys0401E
(Roper Scientific Germany, Ottobrunn, Germany), DMRA2
(Leica Microsystems, Wetzlar, Germany) and Leica
Cytogenetic Workstation (CW4000; Leica Microsystems
Imaging Ltd, Cambridge, UK).
Western blotting analysis
The protein samples (10 µg total proteins) were combined
with gel-loading buffer, heated to 95°C for 10 min, and then
separated on 12% polyacrylamide gels. The proteins were
subsequently transferred onto PVDF membranes (Invitrogen)
and blocked overnight at 4°C in 3% BSA/PBS. The membranes
were incubated at room temperature with anti-SS18 antibody
for 4 h (SYT; H-80, Santa Cruz Biotechnology) or anti-SSX1
antibody (FL-188, Santa Cruz Biotechnology). β-actin (Sigma,
Saint Louis, USA) was used as a loading control. After washing
with PBS/0.05% Tween-20, the filters were incubated with
alkaline phosphatase-conjugated antibodies. The protein signal
was visualized using FLA-3000 (Fujifilm).
Cell proliferation assay
The plasmid pEGFP (control group) or pEGFP-tSSX2
(tSSX2 group) was transfected into SYO-1 cells cultured in 60
mm culture dish, and split into 4 plates of 60 mm cell culture
dishes 48 h after transfection. The transfectants expressing the
fluorescent proteins were observed and counted under a
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fluorescence microscope 4, 6 and 8 days after transfection.
Ratio of the number of cells on days 6 and 8 to that of day 4
was calculated, and compared between tSSX2 and the control
group.
Colony formation assay
SYO-1 cells were grown in 90 mm culture dish and were
transfected with the plasmid pEGFP (control group) or pEGFP-
tSSX2 (tSSX2 group), split into 10 plates of 60 mm culture
dishes 48 h after transfection, selected with 400 µg/mL of G418
for two weeks, and stained with Giemsa stain solution after 4%
formaldehyde fixation.
Statistical analysis
Comparison between the two groups in the cell proliferation
assay was performed using t-test and p < 0.05 were
considered statistically significant. StatView version 5.0 (SAS
Institute Inc., Cary, North Carolina) was used for statistical
analysis.
Supporting Information
Figure S1.  Localization of synovial sarcoma-related
proteins by fluorescence immunocytochemistry. HEK293
cells were transfected with pCMV-Tag2B-SS18, pCMV-Tag2B-
SSX2, and pCMV-Tag2B-SS18-SSX2, and analyzed by
fluorescence immunocytochemistry with anti-SS18 and anti-
SSX antibodies. The transfected cells with SS18 and SS18-
SSX2 were reacted with anti-SS18 antibody (upper and middle,
respectively), and the SSX2 transfectant was reacted with anti-
SSX antibody (lower). Left, antibody reaction using Alexa 594-
conjugated secondary antibody; middle, Hoechst33342
staining; right, merged image. The scale bars are 5-µm long.
(TIF)
Figure S2.  Localization of synovial sarcoma-related fusion
proteins in HEK293 cells. Cells expressing GFP-tagged
proteins were observed under a fluorescence microscope. A,
GFP-SS18; B, GFP-SSX1; C, GFP-SSX2; D, GFP-SS18-
SSX1; E, GFP-SS18-SSX2; F, GFP. Scale bars indicate 5 µm.
(TIF)
Figure S3.  Confirmation of expression of recombinant
proteins by Western blotting. A: HEK293 cells were
transfected with pEGFP (lane 1); pEGFP-SS18 (lane 2, about
79 kDa); pEGFP-SS18-SSX1 (lane 3, about 83 kDa); pEGFP-
SS18-SSX2 (lane 4, about 83 kDa); pEGFP-tSS18 (lane 5,
about 77 kDa); pDsRedmonomer-tSS18 (lane 6, about 81
kDa); and pDsRedmonomer (lane 7); and the cell extracts were
detected by western blotting with anti-SS18 antibody. B:
HEK293 cells were transfected with pEGFP (lane 1); pEGFP-
SSX1 (lane 2, about 51 kDa); pEGFP-tSSX1 (lane 3, about 38
kDa); pDsRedmonomer-tSSX1 (lane 4, about 42 kDa);
pDsRedmonomer (lane 5); pEGFP (lane 6); pEGFP-SSX2
(lane 7, about 51 kDa); pEGFP-tSSX2 (lane 8, about 38 kDa);
pDsRedmonomer-tSSX2 (lane 9, about 42 kDa); and
pDsRedmonomer (lane 10); the cell extracts were detected
using western blotting with anti-SSX antibody.
(TIF)
Figure S4.  Changes in the localization of SS18-SSX1 when
co-expressed with DsRedmonomer tagged truncated SS18
or SSX1 proteins in SYO-1 cells. A, co-expression of GFP-
SS18-SSX1 (A1) and DsRedmonomer-tSS18 (A2); B, co-
expression of GFP-SS18-SSX1 (B1) and DsRedmonomer-
tSSX1 (B2). Scale bars indicate 5 µm.
(TIF)
Figure S5.  Changes in the localization of SS18-SSX2 when
co-expressed with DsRedmonomer-tSS18 or -tSSX2
proteins in HEK293 cells. pEGFP-SS18-SSX2 (2 µg) was
transfected in HEK293 cells with 6 µg of pDsRedmonomer
(left), pDsRedmonomer-tSSX2 (middle), and
pDsRedmonomer-tSS18 (right). Upper, GFP protein; middle,
DsRedmonomer protein; lower, merged image. White arrow
shows a cell with speckled pattern of SS18-SSX2 localization
in which DsRedmonomer-tSSX2 was not expressed. Scale
bars indicate 10 µm.
(TIF)
Figure S6.  Changes in the localization of SS18-SSX when
co-expressed with DsRedmonomer tagged truncated
SS18, SSX1 or SSX2 proteins in HEK293 cells. A, co-
expression of GFP-SS18-SSX1 (A1) and DsRedmonomer-
tSS18 (A2); B, co-expression of GFP-SS18-SSX2 (B1) and
DsRedmonomer-tSS18 (B2): C, co-expression of GFP-SS18-
SSX1 (C1) and DsRedmonomer-tSSX1 (C2); D, co-expression
of GFP-SS18-SSX2 (D1) and DsRedmonomer-tSSX2 (D2).
Scale bars indicate 5 µm.
(TIF)
Figure S7.  Effect of DsRedmonomer-tSSX2 and -tSS18 on
GFP-SS18-SSX2 expression in transfected HEK293 cells.
Plasmid pEGFP-SS18-SSX2 (2 µg) was transfected into
HEK293 cells with 6 µg of pDsRedmonomer (lane 1),
pDsRedmonomer-tSSX2 (lane 2), and pDsRedmonomer-tSS18
(lane 3), and the total extracts (10 µg) were analyzed by
western blotting with anti-SS18 antibody (upper), anti-FLAG
antibody (middle), and anti-β actin antibody (lower). The
pDsRedmonomer vector contains the FLAG-tag.
(TIF)
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